Potential SARS-CoV-2 antiviral to be tested in human lung cells
Posted: 24 May 2021 | Victoria Rees (Drug Target Review) | No comments yet
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
A lead synthetic anti-infective has progressed to the next stage of investigation, the SARS-CoV-2 antiviral screening programme at the Commonwealth Scientific and Industrial Research Organization (CSIRO), Australia.
Developed by Recce Pharmaceuticals, the researchers say that the antiviral, named RECCE® 327 (R327), showed promise at the Doherty Institute, Australia, in initial Stage 1 tests.
“These encouraging results continue to reinforce our confidence in the potential of R327 against SARS-CoV-2 as another line of defence in the arsenal against COVID-19,” said non-executive chairman Dr John Prendergast. “We are keen to continue our work with CSIRO in Stage 2 of the Anti-Viral Screening Program.”
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
According to its developers, high concentrations of R327 (13,333 ppm and 40,000 ppm) showed a four-log reduction in SARS-CoV-2 viral genome numbers as measured by reverse transcription polymerase chain reaction (RT-PCR), but severe cellular toxicity was observed in vero cells at these concentrations. A half maximal cytotoxic concentration (CC50) of 5,108 ppm was calculated for R327.
R327 reduced SARS-CoV-2 viral genome copy numbers at 4,444 ppm and was accompanied by reduced infectious virus titres, allowing a half maximum inhibitory concentration (IC50) calculation of 2,046 ppm. At 4,444 ppm, R327 showed some toxicity, with a rounded cell morphology seen on microscopy.
R327 has been shown to be effective and not highly toxic at a small window of concentrations in the preliminary in vitro testing in vero cells and so received a qualified recommendation to proceed to Stage 2 of the programme for further testing in normal human bronchial epithelial (NHBE) cells grown at the air-liquid interface to be conducted by CSIRO, with anticipated results towards the end of the year.
According to Recce Pharmaceuticals, further testing must be completed in order to determine whether R327 will show an inhibitory effect against the SARS-CoV-2 virus without associated toxicity.
Related topics
Drug Development, Drug Leads, In Vitro, Therapeutics, Toxicology
Related conditions
Covid-19
Related organisations
Commonwealth Scientific and Industrial Research Organisation (CSIRO), Doherty Institute, Recce Pharmaceuticals
Related people
Dr John Prendergast
